Garciaz, S.; Saillard, C.; Hicheri, Y.; Hospital, M.-A.; Vey, N.
Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance. Cancers 2021, 13, 5608.
https://doi.org/10.3390/cancers13225608
AMA Style
Garciaz S, Saillard C, Hicheri Y, Hospital M-A, Vey N.
Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance. Cancers. 2021; 13(22):5608.
https://doi.org/10.3390/cancers13225608
Chicago/Turabian Style
Garciaz, Sylvain, Colombe Saillard, Yosr Hicheri, Marie-Anne Hospital, and Norbert Vey.
2021. "Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance" Cancers 13, no. 22: 5608.
https://doi.org/10.3390/cancers13225608
APA Style
Garciaz, S., Saillard, C., Hicheri, Y., Hospital, M.-A., & Vey, N.
(2021). Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance. Cancers, 13(22), 5608.
https://doi.org/10.3390/cancers13225608